Literature DB >> 15951958

A high frequency of germline BRCA1/2 mutations in western Sweden detected with complementary screening techniques.

Annika Bergman1, Anna Flodin, Yvonne Engwall, Eva L Arkblad, Kerstin Berg, Zakaria Einbeigi, Tommy Martinsson, Jan Wahlström, Per Karlsson, Margareta Nordling.   

Abstract

Dominant inheritance is presumed in 6-10% of breast and ovarian cancers. Mutations in BRCA1 and BRCA2 genes are the most commonly identified causative genes in such families. The frequency of mutation carriers with breast/ovarian cancer depends on the population studied, and display considerable variation that coincides with ethnic and geographical diversity. Mutation analyses were performed in 143 families registered at the Cancer Genetic Counseling Clinic of western Sweden. In a thorough mutation screening procedure, the entire BRCA1 and BRCA2 genes were analyzed using a combination of complementary mutation detection techniques. Mutations in either BRCA1 or BRCA2 were detected in 36% (52 out of 143) of all screened families. All families were clinically evaluated regarding age at diagnosis, type of cancer and number of cancer cases in the family. Among high-risk families, the mutation detection rate was 39% (46 out of 117). The detection rate observed among families with cases of ovarian cancer (42 out of 62, 68%), was substantially higher than in families with only breast cancer (10 out of 81, 12%). Age at ovarian cancer did not seem to have an effect on the detection rate. The analyses revealed 11 frameshift mutations, 4 nonsense mutations and 2 large deletions. Notably, the BRCA1 c.3171ins5 mutation accounted for 34 of 52 (65%) identified mutations. Seven mutations are novel: BRCA1c.409_410del; c.1912T>G; c.2228_2229del; c.3029delA; c.3433delA, a large deletion covering exons 1-3 of BRCA1and one BRCA2 mutation; BRCA2c.6287_6290del. We have shown that the founder mutation BRCA1 c.3171ins5 has a great influence on western Swedish breast/ovarian cancer families along with a high number of mutations unique for the region. In order to achieve a high mutation detection rate we suggest a combination of several detection techniques.

Entities:  

Mesh:

Year:  2005        PMID: 15951958     DOI: 10.1007/s10689-004-5812-2

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  32 in total

1.  The western Swedish BRCA1 founder mutation 3171ins5; a 3.7 cM conserved haplotype of today is a reminiscence of a 1500-year-old mutation.

Authors:  A Bergman; Z Einbeigi; U Olofsson; Z Taib; A Wallgren; P Karlsson; J Wahlström; T Martinsson; M Nordling
Journal:  Eur J Hum Genet       Date:  2001-10       Impact factor: 4.246

2.  Exclusion of large deletions and other rearrangements in BRCA1 and BRCA2 in Finnish breast and ovarian cancer families.

Authors:  J Lahti-Domenici; K Rapakko; K Pääkkönen; M Allinen; H Nevanlinna; M Kujala; P Huusko; R Winqvist
Journal:  Cancer Genet Cytogenet       Date:  2001-09

3.  Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method.

Authors:  Frans B L Hogervorst; Petra M Nederlof; Johan J P Gille; Cathal J McElgunn; Maartje Grippeling; Roelof Pruntel; Rein Regnerus; Tibor van Welsem; Resie van Spaendonk; Fred H Menko; Irma Kluijt; Charlotte Dommering; Senno Verhoef; Jan P Schouten; Laura J van't Veer; Gerard Pals
Journal:  Cancer Res       Date:  2003-04-01       Impact factor: 12.701

4.  Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification.

Authors:  Jan P Schouten; Cathal J McElgunn; Raymond Waaijer; Danny Zwijnenburg; Filip Diepvens; Gerard Pals
Journal:  Nucleic Acids Res       Date:  2002-06-15       Impact factor: 16.971

5.  Rapid detection of novel BRCA1 rearrangements in high-risk breast-ovarian cancer families using multiplex PCR of short fluorescent fragments.

Authors:  Federica Casilli; Zorika Christiana Di Rocco; Sophie Gad; Isabelle Tournier; Dominique Stoppa-Lyonnet; Thierry Frebourg; Mario Tosi
Journal:  Hum Mutat       Date:  2002-09       Impact factor: 4.878

6.  Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families.

Authors:  L C Verhoog; A M van den Ouweland; E Berns; M M van Veghel-Plandsoen; I L van Staveren; A Wagner; C C Bartels; M M Tilanus-Linthorst; P Devilee; C Seynaeve; D J Halley; M F Niermeijer; J G Klijn; H Meijers-Heijboer
Journal:  Eur J Cancer       Date:  2001-11       Impact factor: 9.162

7.  Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer.

Authors:  S Håkansson; O Johannsson; U Johansson; G Sellberg; N Loman; A M Gerdes; E Holmberg; N Dahl; N Pandis; U Kristoffersson; H Olsson; A Borg
Journal:  Am J Hum Genet       Date:  1997-05       Impact factor: 11.025

8.  Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer.

Authors:  B Górski; T Byrski; T Huzarski; A Jakubowska; J Menkiszak; J Gronwald; A Pluzańska; M Bebenek; L Fischer-Maliszewska; E Grzybowska; S A Narod; J Lubiński
Journal:  Am J Hum Genet       Date:  2000-04-28       Impact factor: 11.025

9.  Somatic mutations in the BRCA1 gene in sporadic ovarian tumours.

Authors:  S D Merajver; T M Pham; R F Caduff; M Chen; E L Poy; K A Cooney; B L Weber; F S Collins; C Johnston; T S Frank
Journal:  Nat Genet       Date:  1995-04       Impact factor: 38.330

10.  BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families.

Authors:  K Claes; B Poppe; I Coene; A De Paepe; L Messiaen
Journal:  Br J Cancer       Date:  2004-03-22       Impact factor: 7.640

View more
  9 in total

Review 1.  Impact of germline and somatic BRCA1/2 mutations: tumor spectrum and detection platforms.

Authors:  H Wu; X Wu; Z Liang
Journal:  Gene Ther       Date:  2017-08-03       Impact factor: 5.250

2.  Occurrence of both breast and ovarian cancer in a woman is a marker for the BRCA gene mutations: a population-based study from western Sweden.

Authors:  Zakaria Einbeigi; Annika Bergman; Jeanne M Meis-Kindblom; Anna Flodin; Cecilia Bjursell; Tommy Martinsson; Lars-Gunnar Kindblom; Jan Wahlström; Arne Wallgren; Margareta Nordling; Per Karlsson
Journal:  Fam Cancer       Date:  2007       Impact factor: 2.375

Review 3.  Mutations in context: implications of BRCA testing in diverse populations.

Authors:  Gabriela E S Felix; Yonglan Zheng; Olufunmilayo I Olopade
Journal:  Fam Cancer       Date:  2018-10       Impact factor: 2.375

4.  Triple-negative breast cancers: an updated review on treatment options.

Authors:  K B Reddy
Journal:  Curr Oncol       Date:  2011-08       Impact factor: 3.677

Review 5.  The contribution of BRCA1 and BRCA2 to ovarian cancer.

Authors:  Susan J Ramus; Simon A Gayther
Journal:  Mol Oncol       Date:  2009-02-10       Impact factor: 6.603

6.  BRCA1/BRCA2 founder mutations and cancer risks: impact in the western Danish population.

Authors:  Henriette Roed Nielsen; Mef Nilbert; Janne Petersen; Steen Ladelund; Mads Thomassen; Inge Søkilde Pedersen; Thomas V O Hansen; Anne-Bine Skytte; Åke Borg; Christina Therkildsen
Journal:  Fam Cancer       Date:  2016-10       Impact factor: 2.375

7.  Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control.

Authors:  Ramūnas Janavičius
Journal:  EPMA J       Date:  2010-06-27       Impact factor: 6.543

8.  Contribution of BRCA1 and BRCA2 Germline Mutations to Early Algerian Breast Cancer.

Authors:  Sarra Henouda; Assia Bensalem; Rym Reggad; Nedda Serrar; Leila Rouabah; Pascal Pujol
Journal:  Dis Markers       Date:  2016-02-22       Impact factor: 3.434

9.  Functional analysis of BRCT missense mutations in BRCA1-mutated Chinese Han familial breast cancer.

Authors:  Hong Zhang; Linsen Li; Yuxia Wang; C Cameron Yin; Yuntao Xie; Xijuan Liu; Huirong Ding; Zhihua Tian; Jing Shen; Long He; Miaoran Xia; Xi Ma; Lina Wu
Journal:  Oncol Lett       Date:  2017-09-19       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.